ZNF217: the cerberus who fails to guard the gateway to lethal malignancy

xlomafota13 shared this article with you from Inoreader ZNF217: the cerberus who fails to guard the gateway to lethal malignancy Via American Journal of Cancer Research Am J Cancer Res. 2021 Jul 15;11(7):3378-3405. eCollection 2021. ABSTRACT The aberrant expression of the zinc finger protein 217 (ZNF217) promotes multiple malignant phenotypes, such as replicative immortality, maintenance of proliferation, malignant heterogeneity, metastasis, and cell death resistance, via diverse mechanisms, including transcriptional activation, mRNA N6-methyladenosine (m6A) regulation, and protein interactions. The induction of these cellular processes by ZNF217 leads to therapeutic resistance and patients' poor outcomes. However, few ZNF217 related clinical applications or trials, have been reported. Moreover, looming observations about ZNF217 roles in m6A regulation and cancer immune response triggered significant attention while lacking critical evidence. Thus, in this review, we revisit the literature about ZNF217 and emphasize its importance as a prognostic biomarker for early pr evention and as a therapeutic target. PMID:34354851 | PMC:PMC8332857 View on the web Inoreader. Take back control of your news feed. Follow us on Twitter and Facebook.